Intravenous cidofovir treatment for recalcitrant warts in the setting of a patient with myelodysplastic syndrome

Cidofovir is an acyclic nucleoside phosphonate with broad-spectrum activity against DNA viruses, including human papilloma virus (HPV). However, data on the efficacy of cidofovir in an immunosuppressive setting remain contradictory. We report for the first time on the promotion of the healing of recalcitrant warts in a patient with myelodysplastic syndrome with intravenous cidofovir treatment.     

Efficacy of short‐term oral cobalamin therapy for the treatment of cobalamin deficiencies related to food‐cobalamin malabsorption: A study of 30 patients

Background: It has been suggested that oral cobalamin (vitamin B₁₂) therapy may be an effective therapy for treating cobalamin deficiencies related to food‐cobalamin malabsorption. However, the duration of this treatment was not determined. Patients and method: In an open‐label, nonplacebo study, we studied 30 patients with established cobalamin deficiency related to food‐cobalamin malabsorption, who received between 250 and 1000 μg of oral crystalline cyanocobalamin per day for at least 1 month. Endpoints: Blood counts, serum cobalamin and homocysteine levels were determined at baseline and during the first month of treatment. Results: During the first month of treatment, 87% of the patients normalized their serum cobalamin levels; 100% increased their serum cobalamin levels (mean increase, +167 pg/dl; P < 0.001 compared with baseline); 100% had evidence of medullary regeneration; 100% corrected their initial macrocytosis; and 54% corrected their anemia. All patients had increased hemoglobin levels (mean increase, +0.6 g/dl) and reticulocyte counts (mean increase, +35 × 10⁶/l) and decreased erythrocyte cell volume (mean decrease, 3 fl; all P < 0.05). Conclusion: Our findings suggest that crystalline cyanocobalamin, 250–1000 μg /day, given orally for 1 month, may be an effective treatment for cobalamin deficiencies not related to pernicious anemia.     

In-hospital mortality of surgical patients: is there an empiric basis for standard setting?

Several public and private groups have set minimum procedure-specific volume standards. Such standards reflect concerns about hospital quality and cost. In-hospital mortality rates are often taken as one measure of quality. To learn about variations in in-hospital mortality rates, we analyzed data on patients who underwent any of seven surgical procedures from a national cohort of 521 hospitals observed continuously between 1972 and 1981. On the average, mortality rates fell as the number of procedures performed annually at the hospital rose. Volumes at which mortality rates reached minimum levels were far higher than actual volumes achieved by the vast majority of hospitals. However, knowledge of hospital volumes left the major part of variation among hospitals' procedure-specific mortality rates unexplained. Many hospitals with low volumes of certain procedures had no associated deaths. Hospitals experienced appreciable year-to-year variation in mortality even though mortality rates fell with the number of years the procedure was performed at the hospital. Correlations among mortality rates for the procedures were low, suggesting that variation in rates is procedure rather than hospital specific. State rate-setting programs had no effect on mortality rates associated with the procedures analyzed. For several reasons, we conclude that an adequate statistical basis for setting minimum volume standards does not presently exist.